Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

European Journal of Cancer

Volumn 45, Issue 9, 2009, Pages 1692-1699

  Terwijn, Monique ^a   Feller, Nicole ^a   van Rhenen, Anna ^a   Kelder, Angèle ^a   Westra, Guus ^a   Zweegman, Sonja ^a   Ossenkoppele, Gert ^a   Schuurhuis, Gerrit Jan ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukaemia; Flow cytometry; IL 2 receptor; Intermediate cytogenetics; Prognosis

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 66149095813     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.02.021     Document Type: Article

References (34)

1. Lowenberg B., Griffin J.D., and Tallman M.S. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology. Am Soc Hematol Educ Program (2003) 82-101
2. van Stijn A., Feller N., Kok A., van der Pol M.A., Ossenkoppele G.J., and Schuurhuis G.J. Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. Clin Cancer Res 11 (2005) 2540-2546
3. van der Pol M.A., Feller N., Ossenkoppele G.J., et al. Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis. Leukemia 17 (2003) 1674-1677
4. van Rhenen A., Feller N., Kelder A., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 11 (2005) 6520-6527
5. Feller N., van der Pol M.A., van Stijn A., et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18 (2004) 1380-1390
6. Venditti A., Buccisano F., Del P.G., et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96 (2000) 3948-3952
7. San Miguel J.F., Martinez A., Macedo A., et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90 (1997) 2465-2470
8. Kern W., Voskova D., Schoch C., Hiddemann W., Schnittger S., and Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104 (2004) 3078-3085
9. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
10. Kornblau S.M., Womble M., Qiu Y.H., et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108 (2006) 2358-2365
11. Hess C.J., Feller N., Denkers F., et al. Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia. Haematologica 94 (2009) 46-53
12. Macdonald D., Jiang Y.Z., Swirsky D., et al. Acute myeloid leukaemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor. Brit J Haematol 77 (1991) 43-49
13. Carron J.A., and Cawley J.C. IL-2 and myelopoiesis: IL-2 induces blast cell proliferation in some cases of acute myeloid leukaemia. Brit J Haematol 73 (1989) 168-172
14. Pizzolo G., Rigo A., Zanotti R., et al. Alpha (p55) and beta (p75) chains of the interleukin-2 receptor are expressed by AML blasts. Leukemia 7 (1993) 418-425
15. Morris J.C., and Waldmann T.A. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 59 Suppl. 1 (2000) i109-i114
16. Schumann R.R., Nakarai T., Gruss H.J., et al. Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. Blood 87 (1996) 2419-2427
17. Nakase K., Kita K., Miwa H., et al. Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis. Leukemia 21 (2007) 326-332
18. Mrozek K., Marcucci G., Paschka P., Whitman S.P., and Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 109 (2007) 431-448
19. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
20. Cloos J., Goemans B.F., Hess C.J., et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20 (2006) 1217-1220
21. Rombouts W.J., Blokland I., Lowenberg B., and Ploemacher R.E. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14 (2000) 675-683
22. Iwasaki T., Katsumi A., Kiyoi H., et al. Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. Eur J Haematol 81 (2008) 454-460
23. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358 (2008) 1909-1918
24. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. New Engl J Med 358 (2008) 1919-1928
25. Hess C.J., Berkhof J., Denkers F., et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol 25 (2007) 1209-1215
26. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
27. Spiekermann K., O'Brien S., and Estey E. Relapse of acute myelogenous leukemia during low dose interleukin-2 (IL-2) therapy. Phenotypic evolution associated with strong expression of the IL-2 receptor alpha chain. Cancer 75 (1995) 1594-1597
28. Cozzolino F., Torcia M., Bettoni S., et al. Interleukin-1 and interleukin-2 control granulocyte- and granulocyte-macrophage colony-stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia. Int J Cancer 46 (1990) 902-907
29. Weidmann E., Brieger J., Bergmann L., Hoelzer D., and Mitrou P.S. AML blasts variably express interleukin 2 receptor alpha, beta or gamma chains without measurable effects on proliferation, cytokine message expression or surface expression of adhesion molecules upon stimulation with interleukin 2. Leuk Res 19 (1995) 469-476
30. Foa R., Caretto P., Fierro M.T., et al. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Brit J Haematol 75 (1990) 34-40
31. Junghans R.P., and Waldmann T.A. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med 183 (1996) 1587-1602
32. Nakase K., Kita K., Kageyama S., et al. Clinical importance of interleukin-2 receptor alpha-chain expression in acute leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Cancer Detect Prev 21 (1997) 273-279
33. Baer M.R., George S.L., Caligiuri M.A., et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 26 (2008) 4934-4939
34. Chamuleau M.E., Souwer Y., Van Ham S.M., et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 64 (2004) 5546-5550